Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LIT-00505
- Development stage
- Unknown
- Lead developer
- Shanghai LiteDD
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
LIT-00505 is a small molecule inhibitor of Tyrosine Kinase 2 (TYK2) being developed by Shanghai Huiqi Biomedical Technology for the topical treatment of plaque psoriasis. TYK2 is an intracellular kinase that mediates signaling for several cytokines involved in the inflammatory response, including interleukin-23 (IL-23), interleukin-12 (IL-12), and Type I interferons. By selectively inhibiting TYK2, LIT-00505 aims to modulate the immune pathways responsible for the development and progression of psoriasis while potentially avoiding the systemic side effects associated with oral Janus kinase (JAK) inhibitors. The drug is currently being evaluated in Phase 1 clinical trials as an ointment formulation to provide localized therapeutic effects for patients with skin lesions.
Beyond the preview
Go deeper on LIT-00505.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LIT-00505.